



DIVA Investor Conference

Aug 15, 2025



Participants



Vice Chairman & CEO

Gene Chen



GM

Yvonne Liu



Admin VP & Spokesman

Michael Mai



Finance Senior Manager

Angel Chiang

Agenda

一. Company Profile

Admin VP &
Spokesman

Michael Mai

二. 2025 H1 Financial Results

三. Business Update and Outlook

GM

Yvonne Liu

四. Q&A

Vice Chairman &
CEO

Gene Chen

Safe Harbor Notice

We have made forward-looking statements in the presentation. Our forward-looking statements contain information regarding, among other things, our financial conditions, future expansion plans and business strategies. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that these expectations and projections are reasonable, such forward-looking statements are inherently subject to risks, uncertainties, and assumptions about us.

We undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might not occur and our actual results could differ materially from those anticipated in these forward-looking statements.



—Company Profile

Admin VP & Spokesman Michael Mai

DIVA Labs.

Focused on providing high quality precision displays to meet the product requirements of global OEM and ODM customers

Year Established 1995

IPO Year 2013
(Ticker 4153)

Capital (NTD) 587M

No. of Employees 142+

Global Presence

Manufacturing Sites : Taiwan

Sales Offices : 3 Locations Worldwide

R&D : Taiwan

Revenue Breakdown by Geography :

	2023	2024	2025
Americas	37%	46%	48%
Europe	44%	38%	33%
Taiwan	6%	4%	3%
Others	13%	12%	16%

2025 H1 Revenue

NTD\$ 442M (USD\$ 13.8M)

2024 Revenue

NTD\$ 862M (USD\$26.9M)



二. 2025 H1 Financial Results

Admin VP & Spokesman Michael Mai

2025 H1 Highlights

01

Revenue -0.7% YoY in the first Half

- +5.2% for medical, -5.9% for industrial.

02

Operating income and net income attributable to the parent company YoY in the first Half

- Operating income -0.7%, and net income attributable to the parent company -8.5%.

Consolidated Statement of Comprehensive Income(Quarterly)

Unit : NT\$Million

	2025 Q2		2024 Q2		YoY		2025 Q1		QoQ	
	amt	g%	amt	g%	amt	g%	amt	g%	amt	g%
Net Sales	235	100%	223	100%	12	5%	207	100%	28	13%
Cost of Goods Sold	(163)		(152)		(12)		(139)		(24)	
Gross Margin	72	30%	71	32%	0	1%	68	33%	4	5%
Operating Expenses	(40)	-17%	(40)	-18%	(0)		(38)	-18%	(2)	
Operating Income	31	13%	31	14%	0	1%	30	14%	2	5%
Net non-operating Income	(5)		1		(7)		3		(8)	
Profit(Loss) before Tax	26	11%	32	14%	(6)	-19%	32	16%	(6)	-20%
Net Income	26	11%	31	14%	(5)	-17%	25	12%	1	4%
Net income attributable to DIVA	26	11%	31	14%	(5)	-17%	25	12%	1	4%
EPS (NT\$) (a)	\$0.44		\$0.52		-\$0.08		\$0.42		\$0.02	

(a) EPS was calculated based on total weighted-averaged outstanding shares

Consolidated Statement of Comprehensive Income (YTD)


Unit : NT\$Million

	2025 H1		2024 H1		YoY	
					amt	g%
Net Sales	442	100%	445	100%	(3)	-1%
Cost of Goods Sold	(303)		(312)		9	
Gross Margin	140	32%	134	30%	6	4%
Operating Expenses	(78)	-18%	(72)	-16%	(6)	
Operating Income	61	14%	62	14%	(0)	-1%
Net non-operating Income	(3)		3		(5)	
Profit(Loss) before Tax	59	13%	64	14%	(6)	-9%
Net Income	51	11%	55	12%	(5)	-9%
Net income attributable to DIVA	51	11%	55	12%	(5)	-9%
EPS (NT\$) (a)	\$0.86		\$0.94		-\$0.08	

(a) EPS was calculated based on total weighted-averaged outstanding shares


Revenue and Operating Income

Unit : NT\$ Million



Revenue

Unit : NT\$ Million




Operating Income

Consolidated Balance Sheet Highlights


Unit : NT\$ Million

	2025.06.30		2025.03.31		QoQ		2024.06.30		YoY	
	amt	g%	amt	g%	amt	g%	amt	g%	amt	g%
Cash and cash equivalents	643	46%	593	44%	50	8%	608	45%	35	6%
Accounts receivable	262	19%	270	20%	-8	-3%	251	19%	11	4%
Inventories	192	14%	172	13%	20	12%	179	13%	13	7%
Total Assets	1,407	100%	1,334	100%	73	5%	1,339	100%	68	5%
Accounts payable	72	5%	73	5%	-1	-1%	84	6%	-12	-14%
Other payables	281	20%	230	17%	51	22%	175	13%	105	60%
Toal Liabilities	422	30%	370	28%	52	14%	319	24%	103	32%
Total equity	985	70%	964	72%	20	2%	1,019	76%	-34	-3%


Consolidated revenue - by product application




Consolidated revenue - by sales area



Consolidated revenue - by customer segment



Consolidated revenue - by revenue concentration



Company New Website (www.diva.com.tw)



EN TW

Products

Applications

Download

ODM/OEM

HR

Investor

ESG

About



Contact Us

Expert in Medical Monitor Design & Assembly

From Design to Production - Your Complete Display Solution

With over 30 years of expertise in high-end display design and manufacturing, DIVA delivers precise, reliable solutions tailored for diverse and demanding medical applications.


READ MORE →



≡. Business Update and Outlook

GM Yvonne Liu

DIVA's Strategy



2025 H2 Outlook



Exchange Rate & Tariff Impact

- The depreciation of the U.S. dollar affects revenue and gross margin; tariffs do not have a significant impact at this time.



Large-Sized Medical Displays from Qisda's Suzhou Plant

- Shipment volume is expected to gradually increase in H2 2025.



OLED Models for Ultrasound Applications

- We have successfully overcome the OLED burn-in issue and optimized panel lifespan. Shipments are expected to begin by the end of the year.



Standard Product Development and Market Entry

- Developing cost-competitive Off-The-Shelf (OTS) models. The QDII series, our standard platform products, will begin shipping in October.



四. Q&A



Thank you